• head_banner_01

RhoVac Cancer Peptide Vaccine RV001 ga-enweta ikike site n'aka ụlọ ọrụ ọgụgụ isi nke Canada.

Canada oge 2022-01-24, RhoVac, a na-emepụta ọgwụ ụlọ ọrụ lekwasịrị anya na akpụ immunology, mara ọkwa na ya patent ngwa (No. 2710061) maka cancer peptide ogwu RV001 ga-ikike site Canadian Intellectual Property Office (CIPO).Na mbụ, ụlọ ọrụ ahụ enwetala patent metụtara RV001 na United States, Europe na Japan.Onyinye patent a ga-enye nchebe sara mbara maka RV001 na ahịa ndị bụ isi ma bulie ihe mgbochi patent nke ụlọ ọrụ ahụ.

Dịka ngwa ikike ikike enyere na mbụ, patent a na-ekpuchi ọgwụ mgbochi ọrịa kansa RV001 na ụdị ya dị iche iche, yana iji ya na ọgwụgwọ/mgbochi RhoC na-egosipụta ọrịa kansa metastatic.N'ime ha, RhoC bụ antigen metụtara tumor (TAA) nke a na-egosipụta n'ọtụtụ dị iche iche.Ozugbo enyere ya, patent ahụ ga-ekubi ume na 2028-12 ma a na-atụ anya ịgbatị ya ma ị nweta Asambodo Nchekwa mgbakwunye (CSP).

01 Onilcamotide

Onilcamotide bụ ọgwụ mgbochi ọrịa kansa nke nwere peptides immunogenic ewepụtara n'aka onye otu ezinụlọ Ras homologous C (RhoC), nke enwere ike ime emulsified na mgbochi mgbochi montanide ISA-51, yana ihe omume immunomodulatory na antitumor nwere ike.nchịkwa subcutaneous nke Onilcamotide na-akpali usoro ahụ ji alụso ọrịa ọgụ na-ebuli nzaghachi na-atọ ọchị na cytotoxic T lymphocyte (CTL) na RhoC na-egosipụta mkpụrụ ndụ tumo, si otú ahụ na-edina mkpụrụ ndụ tumor.

2020-11, FDA nyere RV001 aha Fast Track.

Onilcamotide

02 Nnwale ụlọ ọgwụ

N'afọ 2018, a kwadoro nnwale ụlọ ọgwụ nke Phase I/IIa nke Onilcamotide maka ọgwụgwọ ọrịa kansa prostate, na ngụkọta nke ndị ọrịa 21 debanyere aha.Nsonaazụ gosiri na Onilcamotide dị mma yana nnabata nke ọma.Na mgbakwunye, ndị ọrịa nwetara nzaghachi mgbochi siri ike na nke na-adịgide adịgide na-esochi ọgwụgwọ.Na 2021, nlebanya nke 19 n'ime isiokwu ndị a, afọ atọ ka emechara ọgwụgwọ RhoVac, gosipụtara na isiokwu ndị a enwebeghị metastases ma ọ bụ nweta ọgwụgwọ ọzọ yana enweghị ọganihu prostate-specific antigen (PSA)..N'ime ndị a, isiokwu 16 enweghị PSA a na-achọpụta, na isiokwu 3 nwere ọganihu PSA ngwa ngwa.PSA bụ protein nke prostate gland na-emepụta, a na-ejikwa ya achọpụta ọganihu nke ọrịa kansa prostate mara.

N'afọ 2019, a malitere RV001 Phase IIb Clinical BraVac (randomized, double-kpuru, ebe a na-achịkwa ebebo) iji nyochaa ịdị irè ya na igbochi ma ọ bụ igbochi mmepe nke ọrịa cancer prostate metastatic mgbe ịwachara ahụ / radieshon.Nnwale ụlọ ọgwụ IIb a bụ ihe ọmụmụ mba ụwa, ọtụtụ ihe na-ewe ndị mmadụ na mba Europe 6 (Denmark, Finland, Sweden, Belgium, Germany, na United Kingdom) na United States.Ọnwụnwa ahụ emechara n'ọrụ ndị ọrịa na 2021-09, yana mkpokọta ihe dị ka isiokwu 175 debanyere aha, ma ga-akwụsị na 2022H1.Na mgbakwunye, RhoVac na-ezube ime nyocha nyocha izizi nke ebumnuche iji nye ihe akaebe maka mgbasawanye nke RV001 na egosi.

Na mgbakwunye, kọmitii na-ahụ maka nchekwa ahụ mekwara nyocha nchekwa nwa oge nke RV001 na 2021-07, ọ nweghịkwa ihe ọjọọ a na-atụghị anya ya ahụrụ, bụ nke dabara na nsonaazụ ụlọ ọgwụ mbụ nke I/II gara aga.


Oge nzipu: Feb-17-2022